ArticleBMC biotechnology2026
Green-synthesized Desertifilum silver nanoparticles induce BAX/BCL-2 mediated apoptosis in Ehrlich carcinoma.
Article in BMC biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGreen and biogenic silver nanoparticles (AgNPs) are widely researched as anticancer treatments; nevertheless, in vivo data on cyanobacteria-derived formulations and their apoptotic mechanisms are limited.
objectivesTo assess the antitumor activity, hematological safety, and apoptosis-related pathways of Desertifilum tharense-derived AgNPs, provided either independently or in conjunction with Desertifilum exopolysaccharides (EPS), in a mouse Ehrlich cell carcinoma (ECC) model.
methodsMale Swiss albino mice were assigned to five groups: healthy control, AgNP toxicity control, tumor control, AgNP-treated tumor, and AgNPs + EPS-treated tumor. Endpoints encompassed body weight, thigh tumor volume, hematological profiling, histology, immunohistochemistry identification of cleaved caspase 3, and real-time PCR quantification of BAX, BCL-2, and caspase 3 mRNA, utilizing the BAX/BCL-2 ratio as an indicator of apoptotic equilibrium.
resultsTumor control subjects exhibited significant increases in body weight and tumor volume, along with anemia, leukocytosis, and altered leukocyte differentials. The AgNP-treated groups had markedly decreased tumor sizes and partial restoration of hematological parameters, whereas healthy mice treated solely with AgNP maintained values within physiological limits. Tumor sections from treated mice exhibited significant necrosis and a treatment-dependent increase in cleaved caspase 3 staining, most apparent and widespread in the AgNPs + EPS group. Gene expression analysis demonstrated a considerable upregulation of BAX and caspase 3, alongside a downregulation of BCL-2 in treated tumors, with the combination formulation exhibiting the highest BAX/BCL-2 ratio, indicative of pronounced activation of mitochondria-mediated apoptosis.
conclusionsDesertifilum-derived AgNPs demonstrate in vivo antitumor efficacy against ECC with satisfactory hematological safety and induce caspase 3 dependent, mitochondria-mediated apoptosis via regulation of the BAX/BCL-2 axis. The co-administration with EPS enhances the pro-apoptotic gene and protein profile, endorsing cyanobacteria-based AgNP/EPS systems as viable candidates for future nano-based cancer therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.